This inventor holds 3 USPTO granted patents. Top assignee: Novartis Ag. Active years: 2001-2006.
Company Filing History:
Years Active: 2001-2006
Title: Daqiang Xu: Innovator in Pharmaceutical Chemistry
Introduction
Daqiang Xu is a notable inventor based in Whippany, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of selective COX-2 cyclooxygenase inhibitors. With a total of 3 patents to his name, Xu's work has the potential to impact therapeutic approaches in pain management and inflammation.
Latest Patents
One of Daqiang Xu's latest patents involves certain 5-alkyl-2-arylaminophenylacetic acids and derivatives. This patent discloses compounds of formula I, where various substituents such as methyl, ethyl, chloro, and fluoro are explored. These compounds are designed to act as selective COX-2 cyclooxygenase inhibitors, along with their pharmaceutically acceptable salts and prodrug esters. This innovation highlights Xu's commitment to advancing medical science through targeted drug development.
Career Highlights
Daqiang Xu is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field and contribute to groundbreaking research and development efforts. His work is characterized by a focus on creating effective pharmaceutical solutions that address unmet medical needs.
Collaborations
Throughout his career, Daqiang Xu has worked alongside esteemed colleagues such as Roger A. Fujimoto and Leslie Wighton McQuire. These collaborations have fostered an environment of innovation and have led to the successful development of new pharmaceutical compounds.
Conclusion
Daqiang Xu's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in the medical field. His patents and collaborations reflect a dedication to improving healthcare through scientific advancements.